Overview

Cabozantinib was not designed around a single driver. It inhibits a cluster of receptor tyrosine kinases, and that breadth — rather than potency at one target — is what allows the same 60 mg tablet to appear in renal cell carcinoma, hepatocellular carcinoma and differentiated thyroid cancer. Reading the target list explains the clinical footprint, and also the adverse-event profile that comes with it.

The Receptor Set and What Each Contributes

The recognised targets include MET (hepatocyte growth factor receptor), VEGFR1, VEGFR2 and VEGFR3, RET, AXL, KIT, TRKB, FLT3 and TIE2. MET signalling is associated with invasive growth and with escape from other targeted agents, which is part of the mechanistic argument for using cabozantinib after another agent has failed. VEGFR blockade supplies the antiangiogenic component: tumour vasculature depends on VEGF signalling, and VEGFR-directed tyrosine kinase inhibitors are established therapy in renal and hepatic malignancy.

RET inhibition underlies activity in thyroid carcinoma, while AXL has been linked to mesenchymal phenotype and to resistance states in several tumour types. Cabozantinib's pharmacokinetics reinforce the durability of this multi-target effect: it is cleared largely through CYP3A4-mediated hepatic metabolism, is highly protein bound, and has a reported elimination half-life of roughly 55 hours. That long half-life is why strong CYP3A4 inducers and inhibitors matter clinically, and why patients are advised to avoid grapefruit and St John's wort during treatment.

How Target Breadth Shapes Combination and Sequencing

Because VEGFR inhibition alters the tumour microenvironment as well as the vasculature, cabozantinib became a rational partner for immune checkpoint blockade; the label includes first-line advanced renal cell carcinoma in combination with nivolumab, alongside its single-agent role in advanced RCC. In hepatocellular carcinoma the labelled position is after prior sorafenib, and in differentiated thyroid cancer it is reserved for disease that has progressed following VEGFR-targeted therapy in patients who are radioactive iodine-refractory or ineligible.

The same breadth drives the safety profile. Labels warn of gastrointestinal perforation and fistula formation and of severe haemorrhage, together with thrombotic events, uncontrolled hypertension, osteonecrosis of the jaw, severe diarrhoea, palmar-plantar erythrodysaesthesia, reversible posterior leukoencephalopathy syndrome and proteinuria. Blood pressure, urine protein and oral and skin examination are therefore part of routine monitoring, not optional extras.

FAQ

Q: Why is the same 60 mg dose used across several different cancers? A: Because the labelled dose is set by tolerability and target coverage rather than by tumour site. Cabozantinib blocks a receptor cluster — MET, VEGFRs, RET, AXL and others — that is relevant across renal, hepatic and thyroid disease, so one strength serves several indications with dose modification managed individually.

Q: Does the long half-life change how interactions are handled? A: Yes. With an elimination half-life of about 55 hours and CYP3A4-mediated clearance, exposure shifts from strong CYP3A4 inducers or inhibitors persist for days. Patients are also told to avoid grapefruit and St John's wort, and any dose modification should follow the labeling sequence rather than improvised schedules.

Q: What monitoring accompanies treatment? A: Blood pressure, urine protein, and assessment for abdominal pain or bleeding symptoms should be routine. Dental evaluation before treatment reduces osteonecrosis risk, and diarrhoea, skin reactions on palms and soles, and neurological symptoms such as headache or visual change warrant prompt review.